‘Real world’ tolerability, ease of use, patient satisfaction and reported adherence in CF adults commencing Colobreathe®

S. Cameron, J. Choyce, B. Ahitan, C. Brown, R. Rashid, J.L. Whitehouse, E.F. Nash

Midlands Adult CF Centre, Heart of England NHS Foundation Trust, Birmingham, B9 5SS, UK

BACKGROUND

- Colobreathe® dry powder inhaler (CSDPI) is a new inhaled formulation of colistimethate sodium, recently introduced for CF patients infected with P. aeruginosa.
- In the clinical trial setting, CSDPI has been found to be non-inferior to nebulised TOBI (as measured by change in FEV₁) and rated as easier to use by patients1.
- However, there is currently little ‘real world’ evidence to support these clinical trial findings.
- We therefore conducted this study to assess our initial clinical experience with CSDPI at a large regional UK adult CF centre.

METHODS AND MATERIALS

- This was a prospective observational cohort study.
- We identified patients for a month trial of CSDPI who were clinically intolerant of or demonstrated poor adherence to nebulised colistimethate sodium (NCS).
- At test dose of CSDPI, the following were recorded:
  - Demographics
  - Spirometry
  - Reason for switching to CSDPI
- At 1 month review, the following were documented:
  - Spirometry
  - Side effects
- Patients were asked to compare the following parameters with regards to use of NCS and CSDPI:
  - Ease of use
  - Time taken to perform one dose (including preparation, administration and care of nebuliser equipment or inhaler device)
  - Satisfaction
  - Estimated adherence
- Patients were also asked to rate their:
  - Likelihood of continuing with CSDPI
  - Treatment preference

RESULTS (continued)

Other outcomes

- CSDPI was reported to be easier to use than NCS and less time consuming.
- All patients who tolerated a full month of CSDPI, expressed a preference for this rather than NCS and planned to continue long-term, despite some initial reports of device functioning issues.

Data in the following tables reflects patients who had used NCS for at least 1 month consistently in the preceding 12 months and who were continuing with CSDPI at 1 month review.

Preparation and administration

<table>
<thead>
<tr>
<th>Parameter</th>
<th>NCS (IQR 7-9)</th>
<th>CSDPI (IQR 1-2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median ease of preparation (VAS 1-10, 1 = very easy)</td>
<td>5 (IQR 3-8)</td>
<td>1 (IQR 1-2)</td>
</tr>
<tr>
<td>Median ease of administration (VAS 1-10, 1 = very easy)</td>
<td>4 (IQR 3-7)</td>
<td>2 (IQR 1-3)</td>
</tr>
<tr>
<td>Median time required for one dose (minutes)</td>
<td>25 (IQR 20-30)</td>
<td>3 (IQR 2-4)</td>
</tr>
</tbody>
</table>

Satisfaction

<table>
<thead>
<tr>
<th>Parameter</th>
<th>NCS (IQR 5-8)</th>
<th>CSDPI (IQR 2-3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median time required for one dose (VAS 1-10, 1 = very satisfied)</td>
<td>8 (IQR 7-9)</td>
<td>1 (IQR 1-2)</td>
</tr>
<tr>
<td>Median degree of interference with QOL (VAS 1-10, 1 = no interference)</td>
<td>6 (IQR 5-7)</td>
<td>2 (IQR 2-3)</td>
</tr>
<tr>
<td>Median overall satisfaction with therapy (VAS 1-10, 1 = very satisfied)</td>
<td>6 (IQR 5-7)</td>
<td>2 (IQR 2-3)</td>
</tr>
<tr>
<td>Median satisfaction with Colobreathe® device (VAS 1-10, 1 = very satisfied)</td>
<td>3 (IQR 2-5)</td>
<td></td>
</tr>
<tr>
<td>Median likelihood to continue long-term with Colobreathe® (VAS 1-10, 1 = very likely)</td>
<td>1 (IQR 1-2)</td>
<td></td>
</tr>
</tbody>
</table>

Patient comments regarding Colobreathe®

- “It’s a very good product. I can’t believe how much of a difference it has made to me in terms of convenience and time.”
- “It’s easy to use. I can take it in my handbag and use it on the move.”
- “It saves time and it’s easier to organise within my treatment plan. I’m excited about when the manufacturers get the inhaler design right.”
- “I tolerated Promixin® better but the ease of doing Colobreathe® outweighs the chest tightness I get with it.”
- “I’ve sometimes breathed in bits of capsule and I’m concerned that they might be going onto my lungs.”
- “I’m very disappointed with the design of the device and the way the capsules fracture. When this happens there can be a large influx of powder at one time which causes coughing – I then feel I’m losing the powder that I’ve breathed in.”
- “I’m worried that I may not always be getting a full dose. Sometimes when the capsules crack, powder is left in the inhaler or it gets stuck behind the pieces of broken capsule and I have to try and shake/open the capsule to free the trapped powder.”
- “Powder starts to build up on the inside of the inhaler. This stops the capsules from spinning properly and sometimes I get a ‘gush’ of powder and sometimes very little. A supply of two inhalers rather than one a month would be better.”
- “Sometimes bits of the capsule get stuck in the inhaler and I have to use a pencil to get them out.”

CONCLUSIONS

- Despite reporting significant difficulties with the Colobreathe®, all patients who tolerated a full month of Colobreathe® expressed a preference for this rather than nebulised colistimethate sodium and planned to continue long-term.
- Early real world evidence suggests that Colobreathe® is well tolerated, easier to use, less inconvenient and associated with improved adherence compared to nebulised colistimethate sodium.
- Longer-term outcomes are needed to assess whether these benefits are maintained and are associated with improved clinical outcomes.


Acknowledgements: We would like to thank the patients at the West Midlands Adult CF Centre that took part in this study.

RESULTS

- 23 patients (10 male) with median age 31 yrs and FEV₁ 58.5% predicted were recruited.
- 10 patients trialled CSDPI due to intolerance of NCS (INTOL group) and 13 patients due to poor adherence to NCS (ADH group).

Lung function

- Combining both groups, FEV₁ did not change from baseline to 1 month visits in patients who completed a full month of CSDPI. FEV₁, pre-test dose of CSDPI was 59% predicted (IQR 42-85%) and at 1 month review was also 59% predicted (IQR 43-81%) (p=0.04).

Tolerance

- At 1 month review:
  - 7/10 patients in the INTOL group and 12/13 patients in the ADH group successfully tolerated a full month of CSDPI and planned to continue.
  - 4/23 patients discontinued CSDPI before or at 1 month review due to the intolerable side effects of bronchospasm (4/4) and cough (1/4).
- Of the 10 patients continuing with CSDPI, 7/10 reported tolerable side effects of cough (5/7), bronchospasm (1/7), sore throat (1/7).

Adherence

- At 1 month review:
  - In the ADH group, reported adherence was higher with CSDPI (median 100% of doses) compared with NCS (50% of doses) (p=0.002).

- All patients who tolerated a full month of CSDPI preferred CSDPI and planned to continue long-term, despite some initial reports of device functioning issues.

- Data in the following tables reflects patients who had used NCS for at least 1 month consistently in the preceding 12 months and who were continuing with CSDPI at 1 month review.

- Preparation and administration

- Satisfaction

- Patient comments regarding Colobreathe®

- CONCLUSIONS

- Despite reporting significant difficulties with the Colobreathe®, all patients who tolerated a full month of Colobreathe® expressed a preference for this rather than nebulised colistimethate sodium and planned to continue long-term.

- Early real world evidence suggests that Colobreathe® is well tolerated, easier to use, less inconvenient and associated with improved adherence compared to nebulised colistimethate sodium.

- Longer-term outcomes are needed to assess whether these benefits are maintained and are associated with improved clinical outcomes.


Acknowledgements: We would like to thank the patients at the West Midlands Adult CF Centre that took part in this study.